Solid Biosciences Inc.SLDBNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank30
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P30
Within normal range
vs 5Y Ago
-1.4x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2025-56.27%
2024-6.19%
20233.88%
2022-25.99%
2021-37.39%
202038.95%
2019-32.08%
2018-62.40%
2017-114.83%
2016-378.59%